Literature DB >> 25559188

Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

Melissa C Hanson1, Wuhbet Abraham2, Monica P Crespo2, Stephanie H Chen3, Haipeng Liu2, Greg Lee Szeto4, Mikyung Kim5, Ellis L Reinherz5, Darrell J Irvine6.   

Abstract

An HIV vaccine capable of inducing high and durable levels of broadly neutralizing antibodies has thus far proven elusive. A promising antigen is the membrane-proximal external region (MPER) from gp41, a segment of the viral envelope recognized by a number of broadly neutralizing antibodies. Though an attractive vaccine target due to the linear nature of the epitope and its highly conserved sequence, MPER peptides are poorly immunogenic and may require display on membranes to achieve a physiological conformation matching the native virus. Here we systematically explored how the structure and composition of liposomes displaying MPER peptides impacts the strength and durability of humoral responses to this antigen as well as helper T-cell responses in mice. Administration of MPER peptides anchored to the surface of liposomes induced MPER-specific antibodies whereas MPER administered in oil-based emulsion adjuvants or alum did not, even when combined with Toll-like receptor agonists. High-titer IgG responses to liposomal MPER required the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced by incorporating high-Tm lipids in the vesicle bilayer and optimizing the MPER density to a mean distance of ∼10-15 nm between peptides on the liposomes' surfaces. Encapsulation of helper epitopes within the vesicles allowed efficient "intrastructural" T-cell help, which promoted IgG responses to MPER while minimizing competing B-cell responses against the helper sequence. These results define several key properties of liposome formulations that promote durable, high-titer antibody responses against MPER peptides, which will be a prerequisite for a successful MPER-targeting vaccine.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; HIV vaccine; Lipid membrane; Liposome; MPER; Nanoparticle

Mesh:

Substances:

Year:  2015        PMID: 25559188      PMCID: PMC4312707          DOI: 10.1016/j.vaccine.2014.12.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance.

Authors:  Christopher A Lazarski; Francisco A Chaves; Scott A Jenks; Shenhong Wu; Katherine A Richards; J M Weaver; Andrea J Sant
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

4.  The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes.

Authors:  S M Moghimi
Journal:  Biomaterials       Date:  2006-01       Impact factor: 12.479

5.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.

Authors:  Nancy Dos Santos; Christine Allen; Anne-Marie Doppen; Malathi Anantha; Kelly A K Cox; Ryan C Gallagher; Goran Karlsson; Katarina Edwards; Gail Kenner; Lacey Samuels; Murray S Webb; Marcel B Bally
Journal:  Biochim Biophys Acta       Date:  2007-01-03

6.  Activating B cell signaling with defined multivalent ligands.

Authors:  Erik B Puffer; Jason K Pontrello; Jessica J Hollenbeck; John A Kink; Laura L Kiessling
Journal:  ACS Chem Biol       Date:  2007-04-24       Impact factor: 5.100

7.  Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.

Authors:  Mansun Law; Rosa M F Cardoso; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 9.  Critical issues in mucosal immunity for HIV-1 vaccine development.

Authors:  Barton F Haynes; Robin J Shattock
Journal:  J Allergy Clin Immunol       Date:  2008-05-12       Impact factor: 10.793

10.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

View more
  31 in total

1.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

Review 2.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

Review 3.  Vaccine nanoparticles for protection against HIV infection.

Authors:  Marisa E Aikins; Joseph Bazzill; James J Moon
Journal:  Nanomedicine (Lond)       Date:  2017-02-21       Impact factor: 5.307

Review 4.  Self-assembling peptide-based building blocks in medical applications.

Authors:  Handan Acar; Samanvaya Srivastava; Eun Ji Chung; Mathew R Schnorenberg; John C Barrett; James L LaBelle; Matthew Tirrell
Journal:  Adv Drug Deliv Rev       Date:  2016-08-14       Impact factor: 15.470

5.  Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers.

Authors:  Prabhani U Atukorale; Taylor J Moon; Alexandr R Bokatch; Christina F Lusi; Jackson T Routhier; Victoria J Deng; Efstathios Karathanasis
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

6.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

Review 7.  Improving Vaccine and Immunotherapy Design Using Biomaterials.

Authors:  Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

8.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

9.  An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.

Authors:  Shuai Shao; Wei-Chiao Huang; Cuiyan Lin; Mark D Hicar; Celia C LaBranche; David C Montefiori; Jonathan F Lovell
Journal:  Ann Biomed Eng       Date:  2019-12-12       Impact factor: 3.934

Review 10.  Synthetic Nanoparticles for Vaccines and Immunotherapy.

Authors:  Darrell J Irvine; Melissa C Hanson; Kavya Rakhra; Talar Tokatlian
Journal:  Chem Rev       Date:  2015-07-08       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.